Literature DB >> 29949096

Visuospatial Organization and Recall in Cerebellar Ataxia.

Mitchell Slapik1, Sharif I Kronemer2, Owen Morgan1, Ryan Bloes1, Seth Lieberman3, Jordan Mandel1, Liana Rosenthal1, Cherie Marvel4.   

Abstract

Poor visuospatial skills can disrupt activities of daily living. The cerebellum has been implicated in visuospatial processing, and patients with cerebellar injury often exhibit poor visuospatial skills, as measured by impaired memory for the figure within the Rey-Osterrieth complex figure task (ROCF). Visuospatial skills are an inherent aspect of the ROCF; however, figure organization (i.e., the order in which the figure is reconstructed by the participant) can influence recall ability. The objective of this study was to examine and compare visuospatial and organization skills in people with cerebellar ataxia. We administered the ROCF to patients diagnosed with cerebellar ataxia and healthy controls. The cerebellar ataxia group included patients that carried a diagnosis of spinocerebellar ataxia (any subtype), autosomal dominant cerebellar ataxia, or cerebellar ataxia with unknown etiology. Primary outcome measures were organization and recall performance on the ROCF, with supplemental information derived from cognitive tests of visuospatial perception, working memory, processing speed, and motor function. Cerebellar ataxia patients revealed impaired figure organization relative to that of controls. Figure copy was impaired in the patients, but their subsequent recall performance was normal, suggesting compensation from initial organization and copying strategies. In controls, figure organization predicted recall performance, but this relationship was not observed in the patients. Instead, processing speed predicted patients' recall accuracy. Supplemental tasks indicated that visual perception was intact in the cerebellar ataxia group and that performance deficits were more closely tied to organization strategies than with visuospatial skills.

Entities:  

Keywords:  Ataxia; Cerebellum; Cognition; Memory; Organization; Visuospatial

Mesh:

Year:  2019        PMID: 29949096     DOI: 10.1007/s12311-018-0948-z

Source DB:  PubMed          Journal:  Cerebellum        ISSN: 1473-4222            Impact factor:   3.847


  5 in total

1.  ANO10 mutational screening in recessive ataxia: genetic findings and refinement of the clinical phenotype.

Authors:  Lorenzo Nanetti; Elisa Sarto; Anna Castaldo; Stefania Magri; Alessia Mongelli; Davide Rossi Sebastiano; Laura Canafoglia; Marina Grisoli; Chiara Malaguti; Francesca Rivieri; Maria Chiara D'Amico; Daniela Di Bella; Silvana Franceschetti; Caterina Mariotti; Franco Taroni
Journal:  J Neurol       Date:  2018-12-04       Impact factor: 4.849

2.  Can patients with cerebellar disease switch learning mechanisms to reduce their adaptation deficits?

Authors:  Aaron L Wong; Cherie L Marvel; Jordan A Taylor; John W Krakauer
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

3.  Quality of Life Changes Following the Onset of Cerebellar Ataxia: Symptoms and Concerns Self-reported by Ataxia Patients and Informants.

Authors:  Michelle R Joyce; Prianca A Nadkarni; Sharif I Kronemer; Michael J Margron; Mitchell B Slapik; Owen P Morgan; Liana S Rosenthal; Chiadi U Onyike; Cherie L Marvel
Journal:  Cerebellum       Date:  2022-03-25       Impact factor: 3.648

4.  Alteration in topological properties of brain functional network after 2-year high altitude exposure: A panel study.

Authors:  Zhenlong Xin; Xiaoming Chen; Qian Zhang; Jiye Wang; Yibin Xi; Jian Liu; Baojuan Li; Xiaoru Dong; Yiwen Lin; Wenbin Zhang; Jingyuan Chen; Wenjing Luo
Journal:  Brain Behav       Date:  2020-09-09       Impact factor: 2.708

5.  Quantitative susceptibility mapping of basal ganglia iron is associated with cognitive and motor functions that distinguish spinocerebellar ataxia type 6 and type 3.

Authors:  Cherie L Marvel; Lin Chen; Michelle R Joyce; Owen P Morgan; Katherine G Iannuzzelli; Stephen M LaConte; Jonathan M Lisinski; Liana S Rosenthal; Xu Li
Journal:  Front Neurosci       Date:  2022-08-18       Impact factor: 5.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.